Antiviral Drug Remdesivir Shows Promise For Treating Coronavirus
The NIH trial of the antiviral drug, remdesivir which is made by Gilead Sciences and studied all over including at the Saint John’s Cancer Institute Saint John’s Health Center, has released preliminary data analysis from a randomized, controlled trial, that shows hospitalized patients who received remdesivir recovered faster than similar patients who received placebo.
NBC4 recently interviewed Dr. Steven O’Day, M.D., Executive Director of the Saint John’s Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research, about the findings.
Remdesivir is really targeting the virus itself and trying to reduce its ability to replicate and spread.
Remdesivir is really targeting the virus itself and trying to reduce its ability to replicate and spread.
Dr. O’Day cautions, it’s not a cure or a vaccine, but the results of the NIH study are of significant development.